ECSP18002929A - INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES - Google Patents
INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASESInfo
- Publication number
- ECSP18002929A ECSP18002929A ECIEPI20182929A ECPI201802929A ECSP18002929A EC SP18002929 A ECSP18002929 A EC SP18002929A EC IEPI20182929 A ECIEPI20182929 A EC IEPI20182929A EC PI201802929 A ECPI201802929 A EC PI201802929A EC SP18002929 A ECSP18002929 A EC SP18002929A
- Authority
- EC
- Ecuador
- Prior art keywords
- interleukin
- receptor
- inflammatory diseases
- treat inflammatory
- peptidic inhibitors
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 3
- 102100036672 Interleukin-23 receptor Human genes 0.000 title abstract 2
- 101710195550 Interleukin-23 receptor Proteins 0.000 title abstract 2
- 208000027866 inflammatory disease Diseases 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 abstract 1
- 208000037765 diseases and disorders Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Pain & Pain Management (AREA)
- Gastroenterology & Hepatology (AREA)
- Otolaryngology (AREA)
- Emergency Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Abstract
La presente invención proporciona inhibidores peptídicos novedosos del receptor de interleucina 23 y composiciones y métodos relacionados para utilizar estos inhibidores peptídicos para el tratamiento o la prevención de diversas enfermedades y trastornos, incluidas enfermedades intestinales inflamatorias.The present invention provides novel peptide interleukin 23 receptor inhibitors and related compositions and methods for using these peptide inhibitors for the treatment or prevention of various diseases and disorders, including inflammatory bowel diseases.
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/US2015/040658 WO2016011208A1 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US14/800,627 US9624268B2 (en) | 2014-07-17 | 2015-07-15 | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| US201562264820P | 2015-12-08 | 2015-12-08 | |
| US201662281123P | 2016-01-20 | 2016-01-20 | |
| PCT/US2016/042680 WO2017011820A2 (en) | 2015-07-15 | 2016-07-15 | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP18002929A true ECSP18002929A (en) | 2018-03-31 |
Family
ID=57757647
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ECIEPI20182929A ECSP18002929A (en) | 2015-07-15 | 2018-01-15 | INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP3341011A4 (en) |
| JP (1) | JP6858174B2 (en) |
| KR (1) | KR102513978B1 (en) |
| CN (1) | CN108348580B (en) |
| AU (1) | AU2016293619B2 (en) |
| BR (1) | BR112018000691A2 (en) |
| CA (1) | CA2991984A1 (en) |
| CL (3) | CL2018000128A1 (en) |
| CO (1) | CO2018000349A2 (en) |
| CR (1) | CR20180029A (en) |
| DO (1) | DOP2018000010A (en) |
| EA (1) | EA035733B9 (en) |
| EC (1) | ECSP18002929A (en) |
| HK (1) | HK1257747A1 (en) |
| IL (1) | IL256827A (en) |
| MX (1) | MX384213B (en) |
| NI (1) | NI201800008A (en) |
| PE (1) | PE20180571A1 (en) |
| PH (1) | PH12018500086A1 (en) |
| SG (1) | SG10201912066SA (en) |
| SV (1) | SV2018005614A (en) |
| UA (1) | UA123772C2 (en) |
| WO (1) | WO2017011820A2 (en) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LT3495367T (en) | 2012-06-13 | 2021-02-25 | Incyte Holdings Corporation | MODIFIED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS |
| KR102236829B1 (en) | 2013-03-15 | 2021-04-07 | 프로타고니스트 테라퓨틱스, 인코포레이티드 | Hepcidin analogues and uses therof |
| LT2986610T (en) | 2013-04-19 | 2018-04-10 | Incyte Holdings Corporation | Bicyclic heterocycles as fgfr inhibitors |
| AU2015258863B2 (en) | 2014-05-16 | 2019-10-24 | Protagonist Therapeutics, Inc. | Alpha4beta7 integrin thioether peptide antagonists |
| AU2015289642B2 (en) | 2014-07-17 | 2021-02-25 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
| WO2016054411A1 (en) | 2014-10-01 | 2016-04-07 | Protagonist Therapeutics, Inc. | NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS |
| EP3201217A4 (en) | 2014-10-01 | 2018-07-18 | Protagonist Therapeutics Inc. | Novel cyclic monomer and dimer peptides having integrin antagonist activity |
| US10851105B2 (en) | 2014-10-22 | 2020-12-01 | Incyte Corporation | Bicyclic heterocycles as FGFR4 inhibitors |
| MA41551A (en) | 2015-02-20 | 2017-12-26 | Incyte Corp | BICYCLIC HETEROCYCLES USED AS FGFR4 INHIBITORS |
| SG11201706287PA (en) | 2015-02-20 | 2017-09-28 | Incyte Corp | Bicyclic heterocycles as fgfr inhibitors |
| US10787490B2 (en) | 2015-07-15 | 2020-09-29 | Protaganist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| GB2545898B (en) | 2015-12-21 | 2019-10-09 | Sutura Therapeutics Ltd | Improved drug delivery by conjugating oligonucleotides to stitched/stapled peptides |
| WO2017117411A1 (en) | 2015-12-30 | 2017-07-06 | Protagonist Therapeutics, Inc. | Analogues of hepcidin mimetics with improved in vivo half lives |
| EP3432906A4 (en) | 2016-03-23 | 2020-04-01 | Protagonist Therapeutics, Inc. | Methods for synthesizing alpha4beta7 peptide antagonists |
| EP3570864B1 (en) * | 2017-01-18 | 2026-02-18 | Protagonist Therapeutics, Inc. | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases |
| AR111960A1 (en) | 2017-05-26 | 2019-09-04 | Incyte Corp | CRYSTALLINE FORMS OF A FGFR INHIBITOR AND PROCESSES FOR ITS PREPARATION |
| GB2563875B (en) * | 2017-06-28 | 2020-08-19 | Sutura Therapeutics Ltd | Improvements in drug delivery |
| US10278957B2 (en) | 2017-09-11 | 2019-05-07 | Protagonist Therapeutics, Inc. | Opioid agonist peptides and uses thereof |
| EP3749345A4 (en) | 2018-02-08 | 2022-04-06 | Protagonist Therapeutics, Inc. | CONJUGATED HEPCIDIN MIMETICS |
| ES3061844T3 (en) | 2018-05-04 | 2026-04-07 | Incyte Corp | Salts of an fgfr inhibitor |
| MX2020011718A (en) | 2018-05-04 | 2021-02-15 | Incyte Corp | SOLID FORMS OF A FIBROBLAST GROWTH FACTOR RECEPTOR (FGFR) INHIBITOR AND PROCESSES FOR PREPARING THEM. |
| TW202019948A (en) * | 2018-07-12 | 2020-06-01 | 美商領導醫療有限公司 | Peptide inhibitor of interleukin-23 receptor and its use for treating inflammatory diseases |
| US11628162B2 (en) | 2019-03-08 | 2023-04-18 | Incyte Corporation | Methods of treating cancer with an FGFR inhibitor |
| CN110015978B (en) * | 2019-04-29 | 2021-03-19 | 康化（上海）新药研发有限公司 | Synthesis method of O- [2- [ [ (tert-butyloxycarbonyl) amino ] ethyl ] -N- [ fluorenylmethoxycarbonyl ] -L-tyrosine |
| KR20220027215A (en) * | 2019-07-01 | 2022-03-07 | 발리터 인코포레이티드 | Hydrophilic linkers for multivalent peptide conjugates |
| US11591329B2 (en) | 2019-07-09 | 2023-02-28 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| MX2022000397A (en) * | 2019-07-10 | 2022-04-25 | Protagonist Therapeutics Inc | Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases. |
| US12122767B2 (en) | 2019-10-01 | 2024-10-22 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| TWI891666B (en) | 2019-10-14 | 2025-08-01 | 美商英塞特公司 | Bicyclic heterocycles as fgfr inhibitors |
| US11566028B2 (en) | 2019-10-16 | 2023-01-31 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| EP3819307A1 (en) | 2019-11-07 | 2021-05-12 | CytoKi Pharma ApS | Therapeutic derivatives of interleukin-22 |
| WO2021113462A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Derivatives of an fgfr inhibitor |
| CA3163875A1 (en) | 2019-12-04 | 2021-06-10 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| KR20220141808A (en) | 2020-01-15 | 2022-10-20 | 얀센 바이오테크 인코포레이티드 | Peptide inhibitors of interleukin-23 receptors and their use for treating inflammatory diseases |
| CN118063554A (en) * | 2020-01-15 | 2024-05-24 | 詹森生物科技公司 | Peptide inhibitors of interleukin-23 receptor and their use for the treatment of inflammatory diseases |
| US12012409B2 (en) | 2020-01-15 | 2024-06-18 | Incyte Corporation | Bicyclic heterocycles as FGFR inhibitors |
| KR20230030649A (en) * | 2020-06-29 | 2023-03-06 | 유니버시티 오브 워싱턴 | A polypeptide that binds to the human IL23 receptor |
| CN116438456A (en) | 2020-09-11 | 2023-07-14 | 格里姆普斯生物股份有限公司 | Ex vivo protease activity assays for disease detection/diagnosis, staging, monitoring and treatment |
| KR20230110570A (en) * | 2020-11-20 | 2023-07-24 | 얀센 파마슈티카 엔.브이. | Compositions of Peptide Inhibitors of the Interleukin-23 Receptor |
| JP2023145581A (en) * | 2020-11-20 | 2023-10-11 | ヤンセン ファーマシューティカ エヌ．ベー． | Compositions of peptide inhibitors of interleukin-23 receptors |
| TW202304459A (en) | 2021-04-12 | 2023-02-01 | 美商英塞特公司 | Combination therapy comprising an fgfr inhibitor and a nectin-4 targeting agent |
| JP2024522189A (en) | 2021-06-09 | 2024-06-11 | インサイト・コーポレイション | Tricyclic Heterocycles as FGFR Inhibitors |
| EP4352060A1 (en) | 2021-06-09 | 2024-04-17 | Incyte Corporation | Tricyclic heterocycles as fgfr inhibitors |
| EP4370532A4 (en) * | 2021-07-14 | 2025-09-03 | Janssen Biotech Inc | BICYCLIC PEPTIDE INHIBITORS OF THE INTERLEUKIN-23 RECEPTOR |
| AU2022310354A1 (en) * | 2021-07-14 | 2024-02-29 | Janssen Biotech, Inc. | Peptide inhibitors of interleukin-23 receptor |
| TW202330013A (en) | 2021-07-14 | 2023-08-01 | 美商健生生物科技公司 | Lipidated peptide inhibitors of interleukin-23 receptor |
| CA3240982A1 (en) | 2021-12-01 | 2023-06-08 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| US20250223627A1 (en) * | 2022-03-09 | 2025-07-10 | Glympse Bio, Inc. | Fluorogenic substrates for aminopeptidase detection in biofluids |
| CN114751962B (en) * | 2022-03-17 | 2023-11-07 | 北京大学 | Staple peptide, preparation method and pharmaceutical application thereof |
| CN119487048A (en) | 2022-06-30 | 2025-02-18 | 赛诺菲 | Novel peptides as selective IL-23 receptor antagonists |
| CN120435485A (en) * | 2022-11-21 | 2025-08-05 | 詹森药业有限公司 | Synthesis of cyclic peptides |
| WO2024155547A2 (en) * | 2023-01-16 | 2024-07-25 | Janssen Pharmaceutica Nv | Peptide inhibitors of interleukin-23 receptor |
| AU2024210741A1 (en) * | 2023-01-16 | 2025-09-04 | Janssen Pharmaceutica Nv | Peptide inhibitors of interleukin-23 receptor |
| EP4652181A1 (en) * | 2023-01-16 | 2025-11-26 | Janssen Pharmaceutica NV | Polycyclic peptide inhibitors of interleukin-23 receptor |
| KR20250139359A (en) | 2023-01-31 | 2025-09-23 | 얀센 파마슈티카 엔브이 | Method for preparing a crystalline peptide inhibitor of interleukin-23 receptor |
| WO2024227437A1 (en) * | 2023-05-04 | 2024-11-07 | 西藏海思科制药有限公司 | Preparation of peptide inhibitor of interleukin-23 receptor and use thereof |
| EP4471048A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| EP4471049A1 (en) | 2023-06-01 | 2024-12-04 | Zealand Pharma A/S | Peptide inhibitors of interleukin-23 receptor |
| WO2025051920A1 (en) | 2023-09-08 | 2025-03-13 | Sanofi | New peptides as selective il-23 receptor inhibitors |
| CN121909205A (en) | 2023-09-08 | 2026-04-21 | 赛诺菲 | Novel peptides as selective IL-23 receptor inhibitors |
| TW202607011A (en) | 2024-07-12 | 2026-02-16 | 丹麥商西蘭製藥公司 | Peptide inhibitors of interleukin-23 receptor |
| WO2026057052A1 (en) * | 2024-09-14 | 2026-03-19 | 深圳信立泰药业股份有限公司 | Il-23 receptor inhibitor, preparation method therefor, and use thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942492A (en) * | 1996-11-12 | 1999-08-24 | Angstrom Pharmaceuticals, Inc. | Cyclic peptides that bind to urokinase-type plasminogen activator receptor |
| MX2009008241A (en) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Glucagon/glp-1 receptor co-agonists. |
| JP2011501941A (en) * | 2007-07-06 | 2011-01-20 | バロリゼイション エイチエスジェイ， ソシエテ アン コマンディテ | IL-23 receptor antagonists and uses thereof |
| CA2707840A1 (en) | 2007-08-20 | 2009-02-26 | Allozyne, Inc. | Amino acid substituted molecules |
| US10416172B2 (en) * | 2010-03-31 | 2019-09-17 | Medical Diagnostic Laboratories, Llc | Recombinant soluble truncated IL-23 receptor (IL-23R) capable of inhibiting IL-23R-mediated cell signaling |
| US8946150B2 (en) * | 2011-06-14 | 2015-02-03 | Medical Diagnostic Laboratories, LLC. | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| US9169292B2 (en) * | 2011-06-14 | 2015-10-27 | Medical Diagnostic Laboratories, Llc | Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof |
| AU2014331812B2 (en) * | 2013-10-09 | 2019-01-17 | Bausch Health Ireland Limited | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
| AU2015289642B2 (en) * | 2014-07-17 | 2021-02-25 | Protagonist Therapeutics, Inc. | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases |
-
2016
- 2016-07-15 UA UAA201801482A patent/UA123772C2/en unknown
- 2016-07-15 CR CR20180029A patent/CR20180029A/en unknown
- 2016-07-15 CA CA2991984A patent/CA2991984A1/en active Pending
- 2016-07-15 BR BR112018000691A patent/BR112018000691A2/en not_active IP Right Cessation
- 2016-07-15 KR KR1020187004612A patent/KR102513978B1/en active Active
- 2016-07-15 EA EA201890325A patent/EA035733B9/en not_active IP Right Cessation
- 2016-07-15 PE PE2018000053A patent/PE20180571A1/en unknown
- 2016-07-15 JP JP2018501178A patent/JP6858174B2/en active Active
- 2016-07-15 HK HK19100122.0A patent/HK1257747A1/en unknown
- 2016-07-15 MX MX2018000542A patent/MX384213B/en unknown
- 2016-07-15 WO PCT/US2016/042680 patent/WO2017011820A2/en not_active Ceased
- 2016-07-15 EP EP16825301.1A patent/EP3341011A4/en not_active Withdrawn
- 2016-07-15 AU AU2016293619A patent/AU2016293619B2/en active Active
- 2016-07-15 CN CN201680049562.2A patent/CN108348580B/en active Active
- 2016-07-15 SG SG10201912066SA patent/SG10201912066SA/en unknown
-
2018
- 2018-01-09 PH PH12018500086A patent/PH12018500086A1/en unknown
- 2018-01-10 DO DO2018000010A patent/DOP2018000010A/en unknown
- 2018-01-10 IL IL256827A patent/IL256827A/en unknown
- 2018-01-11 NI NI201800008A patent/NI201800008A/en unknown
- 2018-01-15 CO CONC2018/0000349A patent/CO2018000349A2/en unknown
- 2018-01-15 SV SV2018005614A patent/SV2018005614A/en unknown
- 2018-01-15 EC ECIEPI20182929A patent/ECSP18002929A/en unknown
- 2018-01-15 CL CL2018000128A patent/CL2018000128A1/en unknown
- 2018-11-22 CL CL2018003322A patent/CL2018003322A1/en unknown
-
2021
- 2021-02-09 CL CL2021000343A patent/CL2021000343A1/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NI201800008A (en) | INTERLEUKIN 23 RECEPTOR PEPTIDIC INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES | |
| AR119389A1 (en) | INTERLEUKIN-23 RECEPTOR PEPTIDE INHIBITORS AND THEIR USE TO TREAT INFLAMMATORY DISEASES | |
| CY1122344T1 (en) | BLAUTIA STERCOSIS AND WEXLERAE FOR USE IN THE THERAPEUTIC TREATMENT OF INFLAMMATORY AND AUTOIMMUNE DISEASES | |
| BR112022000328A2 (en) | Interleukin-23 receptor peptide inhibitors and their use to treat inflammatory diseases | |
| EP4378536A3 (en) | Oral peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory bowel diseases | |
| MX2020001774A (en) | Compositions and methods for treating cholestatic disease. | |
| GT201600233A (en) | COMPOUNDS AND COMPOSITIONS AS AGENTS OF THE TOLL TYPE 7 RECEIVER | |
| EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
| EA201891199A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| EA201692529A1 (en) | METHODS AND COMPOSITIONS FOR THE TREATMENT OF DISORDERS USING FOLLYSTATINE POLYPEPTIDES | |
| EA201890047A1 (en) | COMPOSITIONS CONTAINING BACTERIAL STRAINS | |
| GEP20247593B (en) | Compositions and methods of inhibiting masp-3 for the treatment of various diseases and disorders | |
| EA201792047A1 (en) | NEW CONNECTIONS | |
| MX388562B (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF LYSOSOMAL STORAGE DISORDERS AND DISORDERS CHARACTERIZED BY LYSOSOMAL DYSFUNCTION. | |
| UY37038A (en) | COMPOSITIONS AND METHODS TO DECREASE TAU EXPRESSION | |
| EA201892431A1 (en) | Oligonucleotides for the treatment of eye diseases | |
| EA201792604A1 (en) | AUTOTAXIN INHIBITORS AND THEIR APPLICATIONS | |
| CU20170018A7 (en) | RORC2 PIRROLOPIRIDINE MODULATORS REPLACED WITH METHYL AND TRIFLUOROMETILO | |
| MX2019001634A (en) | AMIDAS COMPOUNDS, PHARMACEUTICAL COMPOSITIONS OF THESE AND METHODS TO USE THEM. | |
| EA201791937A1 (en) | ANTI-INFLAMMATORY POLYPEPTIDES | |
| CL2016002321A1 (en) | Compounds derived from 2-8-5-chloropyrimidin-2-ylamino-6,7,8,9-tetrahydro-5h-pyrido3,2-bindol-5-ylacetic acid, modulators of the prostaglandin d2 receptor pharmaceutical composition and its use for the treatment of diseases allergic immune disorders. | |
| EA202091524A1 (en) | INHIBITORS OF THE PROTEASE 2 ACTIVATED RECEPTOR | |
| MX393805B (en) | MODIFIED PEPTIDES FOR USE IN THE TREATMENT OF NEURODEGENERATIVE DISORDERS. | |
| MX383460B (en) | NOVEL PEPTIDE DERIVATIVES AND THEIR USES. | |
| PH12017501694A1 (en) | Compositions for the treatment of fibrosis and fibrosis-related diseases |